Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated (CORT) Revenue
Annual & quarterly revenue history · segment & region breakdown
CORT · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsCorcept Therapeutics Incorporated trailing twelve-month (TTM) revenue is $0.77B, an increase of 12.79% year-over-year from $0.76B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.76B | +$0.09B | +12.79% |
| 2024-12-31 | $0.68B | +$0.19B | +39.94% |
| 2023-12-31 | $0.48B | +$0.08B | +20.04% |
| 2022-12-31 | $0.40B | +$0.04B | +9.80% |
| 2021-12-31 | $0.37B | +$0.01B | +3.42% |
| 2020-12-31 | $0.35B | +$0.05B | +15.46% |
| 2019-12-31 | $0.31B | +$0.06B | +21.99% |
| 2018-12-31 | $0.25B | +$0.09B | +57.82% |
| 2017-12-31 | $0.16B | +$0.08B | +95.77% |
| 2016-12-31 | $0.08B | +$0.03B | +61.72% |
Compare revenue vs peers
BiotechnologyCompare CORT revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Corcept Therapeutics Incorporated receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Corcept Therapeutics Incorporated reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Corcept Therapeutics Incorporated's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CORT revenue · 4 questionsCORT's trailing twelve-month (TTM) revenue is $0.77B. That is an increase of 12.79% year-over-year from $0.76B in FY2025.
▸ Source: FMP · Corcept Therapeutics Incorporated SEC filings · GAAP · Corcept Therapeutics Incorporated SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026